Introduction

Screening: The Public Face
In June 1985, President Ronald Reagan was diagnosed with colon cancer. 1 This announcement stimulated public interest in early detection. The National Cancer Institute provided research support for early detection hoping "to reduce CRC deaths by 50% by the year 2000." of the National Colon Cancer Research Alliance. She was then invited to provide Congressional testimony to the Senate Select Committee on Aging in 2000 about cancer screening. 5 She also provided television coverage of her own colonoscopy, which boosted CRC awareness and galvanized support for colonoscopy as the primary screening tool.
Medicare reimbursement for colonoscopy, national consensus guidelines supporting colonoscopy, and specialty society endorsement of endoscopic screening all accelerated the shift from fecal occult blood testing (FOBT) and flexible sigmoidoscopy (FS) to colonoscopy as a primary tool. Medicare funding for colonoscopy in 2001 was seen as an entitlement, and colonoscopy rapidly became the new "gold standard." I want my colonoscopy was heard loud and clear from patients.
Screening: the Clinician's Dilemma Nationally
In 1963, V Gilbertson, MD, at the Minnesota Cancer Detection Center, began reporting a reduction in the overall incidence of rectosigmoid cancers in the 25-year follow-up of 21,150 patients after removal of all polyps during 113,800 proctosigmoidoscopic exams. 6, 7 The Minnesota prospective randomized-controlled study of FOBT, from 1975 FOBT, from -1978 , randomized 46,551 patients into 3 FOBT screening arms: annual, biennial, and routine care. After 13 years, they reported a 33% and 6% (respectively) reduction in CRC deaths between the two screening groups as compared to the unscreened group. Of note, there was no overall difference in the death rate in the 3 groups during the report of the first 13 years of the study. 8 In 1983, Hardcastle reported a United Kingdom prospective study of FOBT screening of 20,525 patients randomized to screening and control groups. 9 The study findings supported the benefits of FOBT screening with earlier stages of disease at discovery and a presumed survival benefit. In 1996, he reported additional results of 152,000 patients with a survival benefit of 16%. 10 Ongoing trials in Sweden, Denmark, France, and the US during the next 13 years provided more information about FOBT screening. 11, 12 The initial optimistic improvements in survival in the Minnesota study were not replicated in subsequent studies. Using statistical simulation programs, the large differences seen in screening benefits in different studies were reassessed, resulting in a reduction of the expected benefits. 13, 14 As complexity, costs, and time limited the possibility of future randomized studies, investigators focused on case-control studies. The series of studies undertaken at that time were designed to rapidly learn which initiatives would meet the National Cancer Institute goal of improving survival by 2000. In 1988, Selby examined the KPNC Multiphasic Evaluation program and the use of proctosigmoidoscopy within the population, demonstrating a reduction in CRC mortality. 4 In the following year, the same group reported favorable results from FOBT testing. 15 Studies continued over the next decade reflecting on the appropriate screening intervals for FS, colonoscopy, and FOBT testing. 16 A Veterans Administration CRC screening project reported the feasibility of screening colonoscopy and their results. 17, 18 The National Polyp Study reported data that supported the effectiveness of polypectomy in the prevention of CRC. 19 In 2009, the US Preventive Services Task Force (USPSTF) reexamined previous recommendations of FOBT screening for all individuals older than age 50 years (2002, 2008) , and later limited screening beyond age 76 years. 20, 21 In 2009, a large series from the United Kingdom demonstrated the efficacy and benefits of FS screening. 22 In the spring of 2010, the National Institutes of Health State-of-the-Science Conference on Colorectal Screening endorsed FOBT/fecal immunochemical test (FIT) testing as the primary outreach for early detection, noting efficacy for endoscopy modalities. 23 For over a half-century of research, physicians and researchers had learned that CRC screening is effective in providing an early diagnosis, leading to a more favorable stage at presentation, and reducing CRC mortality. They had tested various population-based strategies that changed to accommodate presumed "best practices." They embraced the belief that removal of all advanced neoplasms was a successful primary prevention strategy. They smeared, scoped, and hoped they were on the right path.
Kaiser Permanente Northwest Program: 1980-2010
From 1980 to early 1985, preventive care services were primarily delivered through the KPNW Health Appraisal Program, an Allied Health Practitioner-based clinic for routine physical examination. CRC screening was done using Hemoccult II kits (Beckman-Coulter; Brea, CA) with a 3-day dietary restriction. Though there were variations with instructions for diet, indications, collection, and laboratory processing, the most significant reason for the limited effectiveness was that most positive-FOBT patients did not receive a radiographic or endoscopic clearance of the colon. The lack of a standardized workup was reflected in the 1980 screen-detection rate of 5%.
By 1983, it was clear the CRC screening was ineffective, so a new … convinced by medical experts that colonoscopy was the "gold standard" and confused by conflicting guidelines … redirection to FOBT/FIT testing was a profound dilemma for the clinician. b , the FS strategy was re-reviewed concluding FS as the best overall option, 26 even though there was clear evidence that FOBT was effective. 27 Using simulation modeling, it was predicted that the cost savings from FS screening would accrue after 35 years, only after the program was in place for 30 years. 28 Until 2005, colonoscopy was primarily reserved for symptomatic patients, though afterwards there was pressure to expand its screening indications. Colonoscopy screening was heavily promoted by the national media, specialty groups, and reimbursed by Medicare. The results of colonoscopy trials broadened the colonoscopy discussion by including secondary "prevention by polypectomy" with the removal of all polyps. 29 Cost-effectiveness of this strategy was questioned at this time. 30 The KPNW Region and the nation were unprepared for the rapid increase in demand for colonoscopy. Since 2005, even with extraordinary efforts to provide timely screening services, KPNW has been unable to meet the demand. Recommending any other screening strategy was felt to be a failure of current best practices, but we noted screen-detection performance was deteriorating.
ORIGINAL RESEARCH & CONTRIBUTIONS
KPNW leaders took the opportunity during the fall immunization campaign in 2006 to restart the FOBT testing program. The decade-long success of FOBT testing (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) produced an 18% (12-24%) screen-detection rate, compared with the FS period (1996-2005) at 9% (5-13%). By 2005, the screen-detection rate declined to 5%, which led to readoption of FOBT testing. On the basis of the flu campaign and internal performance data, FOBT testing was the primary screening recommendation in 2007. Subsequently, FIT replaced FOBT in 2009. 31 The overall results of screendetection are reflected in Figure 1 .
Patients and clinicians were slow to change to a new strategy, convinced by medical experts that colonoscopy was the "gold standard" and confused by conflicting guidelines. This redirection to FOBT/FIT testing was a profound dilemma for the clinician. One physician's description, overheard in the lunchroom, was, "It felt like downshifting to reverse." They needed to trust the redirection, but were faced with the problem of explaining an old strategy that was so actively discouraged just a few years earlier.
Key Elements of Kaiser Permanente Northwest Screening Approach
"The greatest risk factor for a condition that has an effective screening test is the failure to be screened" (Tom Vogt, MD; personal communication; 1991). Following publication of large prospective-randomized studies, Northwest Permanente physicians increased cancer screening in their routine patient health appraisal during their office visits. Although well intentioned, much of the overall population at risk for CRC were never screened employing this strategy.
Over the years, there have been four key elements that have affected KPNW's present success: 1. Measuring the success of the screening efforts by the percentage of population reached, and the number of screen-detected cases found. Since 1990, research has focused on the accuracy of the "best test," rather than patient acceptance, resource availability, cost, and outcomes. 2. Shifting from episodic officebased screening to a populationbased strategy. 4 For this study, screen-detected CRC was defined as the diagnosis of an In-Situ or invasive cancer of the colon and rectum (excluding: anal, squamous cell, cloacogenic, carcinoid, lymphoma, melanoma, or appendiceal cancers) with no symptoms of bleeding, anemia (hemogram parameters were corrected for age and sex), new constipation or diarrhea, abdominal pain, abdominal mass, perforation, or significant nonintentional weight loss. All other patients were considered symptomatic or non-screendetected. This definition of screen detection has remained unchanged for the duration of the review. The intestinal sites were defined as right colon (cecum to splenic flexure), left colon (descending, and sigmoid), and rectal (rectosigmoid and rectum). This site distribution permitted reliable assessments of the impact of flexible sigmoidoscopy on the early detection efforts. Since 1984, the CRC outcomes have been reviewed annually.
In 1989, a Tumor Registry data field of screen-detection was added to the abstraction process to facilitate the review of program performance. Whether a cancer patient diagnosis was made by screen detection, or by symptom, a searchable data field was created, updated, and crosschecked by the Tumor Registry staff. When paper charts were replaced in 1994 with HealthConnect, the review of laboratory tests, pathology, imaging reports, and operation and procedure notes became easier for all reviewers.
To further understand the characteristics of the screen-detected population, a companion database was created so that additional information about screening tests (laboratory, imaging, or endoscopy), personal characteristics (history of polyps or colon cancer, family history), nonscreened symptoms (anemia, bleeding, obstruction, perforation, mass, unexplained weight loss), and delays in care, would supplement the data from the Tumor Registry.
Results
This study sought to determine the best measure of success in detecting CRC.
Screening periods
From 1980-2010, 5458 colorectal cancer patients represented KPNW members who may have been screened by 1 of 4 strategies: office-FOBT, home-FOBT/FIT, FS, or colonoscopy. It was not until 2006, that CRC screening transitioned from office-based testing to the present population-based focus, with active inreach and outreach strategies. Table 2 shows the initiatives that reflected best practice for the normal-risk population during 5-year intervals, with the percentage of screen-detected cases.
Screening tests
Variations Figure 2 demonstrates the infl uence of each test on screen detection in the average-risk population.
From 1995 to 2005, the impact of FS examinations identifying screen-detected cancers was small, fi nding only 68 average-risk patients. Similarly, from 1995 to 2010, the colonoscopy screening only marginally infl uenced the overall screen-detection percentages with only 29 average-risk patients diagnosed out of almost 100,000 colonoscopies. Most colonoscopy testing is done for positive-FOBT/FIT tests and high-risk patients (history of polyps, CRC, and positive family history of CRC). As the number of referrals for colonoscopy screening increased, there were diffi culties in providing screening access for average-risk patients.
Stage
From 1980 to 2010, the screeningsuccess calculation was converted to improved stage of disease based on the effectiveness of the screening percentage as noted in Figure 3 . The main improvements in In-Situ and Localized staging are at the expense of the Regional-Direct stage. There is minimal change in the RegionalNodal and Distant (DIST) disease categories. By comparing the stages between the least effective (5%), present state (33%), and best outcome (100%) scenarios, increasing the percentage of screen-detection provides the best survival. This provides a more realistic picture of the differences found between routine care, and an aggressive screening program. Table 3 illustrates 5-year survival rates for these stages in the KPNW population.
Variations in 5-year survival are based on age, location, and screendetection status. The difference in survival between the screen-detected and symptomatic Regional Lymph Node and Both (REGLB) patient is 79% and 63% respectively ( Figure  4) . We note that even if all patients are screen-detected, some will die of disease. It is estimated that the silent phase for most CRC ranges up to 10 years. We have a 6-to 24-month lead time in patients who refuse an initial workup and subsequently become symptomatic.
Distribution
We have examined the percentage of screen detection during two time frames: 1980 to 1984 and 2007 to 2010, to see if there are signifi cant differences when considering the location of the cancer in the colon. There has been an improvement in the stage of cancers when considering the location of cancer from the right and left colon, and the rectum. The impact of screening technique may infl uence the distribution of cancers as FS and colonoscopy have different ranges, though the infl uence of colonoscopy has been smaller than we may have expected.
We note that there is some shift to lower stages for right and left colon, and rectal tumors, but have Table 4 presents the distribution of stage and screening status, comparing outcomes of most-and least-effective screening prospects.
The KPNW five-year survival outcomes were derived directly from our population. Table 5 demonstrates the survival differences of an effective screening program compared with an unsuccessful testing program.
Incidence
The national SEER database has demonstrated a reduction in the incidence of CRC, but the KPNW incidence of colon and rectal cancer has not changed since 1991 for either men or women. The prospect that approximately 250,000 endoscopies (FS and colonoscopies) since 1991 have not infl uenced the incidence is disappointing. On further examination, there is a reduction in CRC in the left colon with a shift of lesions to the right colon. 33 If this could be attributed to a polypectomy effect, then we would expect to see a reduction in cancers in the rectum, which did not occur.
Screen detection and stage as metrics: The goal of early detection is to discover the cancer in its earliest stage. It is common practice to assess the success of early detection activities by identifying the percentage of early stage disease: In Situ and Localized. The relationship between the (Figure 6 ).
Discussion
We have reviewed the last 30 years of KPNW experience in CRC screening, examining the present success by considering the key elements of the program. We have reviewed the influence of tests, population-based screening, systems of care, and inreach and outreach elements in the KPNW program. Achieving the best screening results in the last 2 years was a culmination of organizational initiatives.
When the KPNW Colon Cancer Task Force in 1984 proposed an improvement process for FOBT testing, we did not expect to continue to readjust the CRC strategy. We performed careful reviews of effectiveness over the years, and changed the strategies on the basis of presumed best practices. The early successes of FOBT testing from 1985 to 1995 were lost for over a decade, as the guidelines shifted to the "best test" and "prevention by polypectomy." As we noted, a continuous decline in screening performance, the outcome data was contributory to a fortunate dramatic reversal of strategy.
In reviewing the overall effects of screening, we have attempted to examine the effective opportunities and benefi ts by comparing the lowest and highest periods of screening. If KPNW expects any greater benefi ts from future screening, we need to redouble efforts to the patients not tested, focusing on the demographics of the patients with advanced stages. This may not be as easy as increasing the number of tests performed. Additionally, we have evidence that screening also improves survival because of withinstage shifting. 34 In summary, early detection of colon cancer saves lives when a program tests the most at-risk people. Using a good test (FOBT/FIT) that is able to reach more people, rather than the "perfect test" that reaches fewer people, transforms an ineffective program into a successful one when the strategy moves from individual testing to population-based screening. Rather than simply measure the number of tests, we identifi ed the rate of screen-detected cases over time. Without high numbers of screening in the at-risk population, the stage shift from DIST and Regional Nodal disease will not occur and will prevent the best population outcomes from occurring. The organizational commitment to move from a testing strategy to a screening program was a key decision in its success. By The early successes of FOBT testing from 1985 to 1995 were lost for over a decade, as the guidelines shifted to the "best test" and "prevention by polypectomy."
